NCT06419634 - Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

May 29, 2024

Primary Completion Date

February 1, 2027

Study Completion Date

September 16, 2030

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndrome

Interventions

DRUG

BMS-986497

Specified dose on specified days

DRUG

Azacitidine

Specified dose on specified days

DRUG

Venetoclax

Specified dose on specified days

Trial Locations (15)

10032

WITHDRAWN

Columbia University Irving Medical Center, New York

13273

NOT_YET_RECRUITING

Local Institution - 0017, Marseille

22031

WITHDRAWN

Local Institution - 0009, Fairfax

31100

NOT_YET_RECRUITING

Local Institution - 0022, Toulouse

60611

NOT_YET_RECRUITING

Local Institution - 0010, Chicago

63108

RECRUITING

Washington University School of Medicine, Siteman Cancer Center, St Louis

75010

NOT_YET_RECRUITING

Local Institution - 0018, Paris

77030

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

06510

RECRUITING

Yale-New Haven Hospital, New Haven

02114

WITHDRAWN

Local Institution - 0007, Boston

RECRUITING

Massachusetts General Hospital, Boston

07601

RECRUITING

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

H3T 1E2

RECRUITING

Jewish General Hospital, Montreal

08036

NOT_YET_RECRUITING

Local Institution - 0020, Barcelona